Navigation Links
ARISTOTLE trial finds new drug may revolutionize the treatment of atrial fibrillation
Date:10/25/2011

Vancouver New research has the potential to revolutionize the treatment of atrial fibrillation (AF), a condition affecting a quarter of a million Canadians which is expected to strike even more in the coming years, as the Canadian population ages.

AF is the most common type of heart arrhythmia and puts those affected at a three to five times greater risk for stroke. Now, there is a new drug poised to battle the condition.

"The majority of patients with atrial fibrillation need an anticoagulant. The current anticoagulant can be a burden for physicians and patients due to its side effects and narrow therapeutic range," Dr. Justin Ezekowitz, from the University of Alberta, told a late breaking clinical trial session at the Canadian Cardiovascular Congress 2011, co-hosted by the Heart and Stroke Foundation of Canada and the Canadian Cardiovascular Congress. It is associated with a risk of bleeding and needs very close monitoring, whereas this new drug is taken twice a day and does not require monitoring. Our trial also shows it is not just equivalent, but better than warfarin for preventing strokes. These are important advantages."

The mainstay of treatment for AF, in which the heart's rhythm becomes very irregular and rapid, has been warfarin, an anticoagulant which has been highly effective in preventing stroke in patients with AF. However, it requires patients to come in to their doctor's office for frequent blood tests, is associated with bleeding, and it also can interact with a variety of foods and drugs that patients might also be taking. Apixaban, a new type of oral anticoagulant known as a factor Xa inhibitor, resulted in fewer strokes (ischemic or hemorrhagic) and fewer systemic embolisms, caused less bleeding and resulted in fewer deaths in patients with atrial fibrillation, said Dr. Ezekowitz.

"We have a drug that can increase reductions in death and stroke and it is safer in terms of bleeding," says Dr. Ezekowi
'/>"/>

Contact: Amanda Bates
amanda@curvecommunications.com
604-306-0027
Heart and Stroke Foundation of Canada
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. HIV Medication Patch Shows Promise in Early Trial
2. Weight Gain Might Raise Endometrial Cancer Risk
3. Significant weight gain in adulthood increased risk for endometrial cancer
4. Timing for clinical trials for stem cell therapy in spinal cord injuries is right
5. Penn-developed online informed consent tool could boost number of patients in cancer clinical trials
6. Major HIV prevention trial in women to drop oral tenofovir arm
7. Company stock prices before public announcements of oncology trial results
8. Smaller, faster trials can improve cancer patient survival
9. Abiraterone acetate improves fatigue in prostate cancer patients, says international clinical trial
10. First Phase III trial of an alpha-pharmaceutical
11. TGen-Virginia G. Piper Cancer Center launches clinical trial for drug to treat lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... (PRWEB) July 30, 2014 Saint ... recently been awarded the Patient-Centered Medical Home 2011 ... National Committee for Quality Assurance. Only one out ... Level I, Level 2, or Level 3 recognition. ... in Patient-Centered Medical Home report faster access to ...
(Date:7/29/2014)... VogueQueen.com, a well-known online supplier, now ... trends in garment fashion by providing graceful and sexy ... an all-inclusive array of sexy dresses , designed ... lot of customers take price into consideration. Worry no ... the purchase more affordable for all clients. , ...
(Date:7/29/2014)... a form of acupuncture where a small ... needles produces significant improvements in fatigue, anxiety ... for early stage breast cancer patients experiencing joint ... (AIs) to treat breast cancer. The results of ... by researchers at the Perelman School of Medicine ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Diabetes is a ... is developed, blood sugar levels are increased, while the production ... produced by the pancreas and which is needed by the ... to overcome and can be very dangerous, as there are ... To learn more about this disorder and read a complex ...
(Date:7/29/2014)... DailyGossip.org reveals in its Stop Sciatica ... new method of naturally overcoming sciatica, in less than ... method ensure sufferers that the cure is simple to ... The new method is described as very fast, as ... an 8 minutes per day treatment plan. , ...
Breaking Medicine News(10 mins):Health News:Saint Luke’s Medical Group Awarded Patient-Centered Medical Home 2011 Level 3 Recognition 2Health News:VogueQueen.com Now Provides Graceful And Sexy Lingerie Collection For August 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 3Health News:Reverse Your Diabetes Today Review Exposes Matt Traverso’s New eBook 2Health News:Stop Sciatica in 8 Minutes Review Reveals the Way to Cure Sciatica Easily 2
... found in foods, study shows , FRIDAY, Aug. 14 ... choline during pregnancy increases the risk of brain and ... focused on two types of neural tube birth defects ... condition in which the brain and skull don,t develop, ...
... named one of the top 10 hospital systems in the ... a leading business and professional information organization based in New ... systems outperformed their peers by a wide margin. They ... more lives, had fewer patient complications, and made fewer patient ...
... , ... On Oct. 9-10, 2009, CRSA will hold ... the organization. An estimated 300 surgeons will be in attendance ... applications for gastrointestinal, colorectal, vascular, transplant, endocrine, oncology and bariatrics. Those ...
... Mich., Aug. 14 Work and economy related stress is taking ... independent survey conducted by American Laser Centers, the largest provider of ... respondents who took part in the survey (47 percent) currently feel ... , , The physical toll of their ...
... /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK), ... great progress being made with the experimental findings ... cure of Multiple Sclerosis not only in their ... unauthorized news link) , , http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20090812/mtl_090812/20090812?hub=Health ...
... , , SAN FRANCISCO, Aug. ... few have success rates higher than 50 percent and none have been ... r al H e alth International (NHI), ... today, its Femmenessence line has been clinically proven to alleviate ...
Cached Medicine News:Health News:University Hospitals in Cleveland named one of the top 10 hospital systems in United States 2Health News:International Robotic Surgery Forum Launches In Chicago 2Health News:International Robotic Surgery Forum Launches In Chicago 3Health News:Hard To Treat Diseases (HTDS.PK) Scientists present encouraging results for the future of Multiple Sclerosis treatment. 2Health News:Hard To Treat Diseases (HTDS.PK) Scientists present encouraging results for the future of Multiple Sclerosis treatment. 3Health News:Hard To Treat Diseases (HTDS.PK) Scientists present encouraging results for the future of Multiple Sclerosis treatment. 4Health News:When it Comes to Natural Remedies for Hormonal Balance, the Proof is in the Clinical Research 2
(Date:7/29/2014)... 2014  Based on its recent analysis of ... & Sullivan recognizes MobileHelp with the 2014 North ... Value Leadership. MobileHelp,s leadership in flexibility across in-home ... progression in personal emergency response, and exemplifies key ... MobileHelp is at the forefront of convenience ...
(Date:7/29/2014)... , July 29, 2014 ... Austria will present data from a Phase ... aims to slow or stop Parkinson,s disease progression. The ... $ 1.5 million grant and will discuss the impact of ... When:   Thursday, July 31, 2014 ...
(Date:7/29/2014)... July 29, 2014   Abide Therapeutics ... to its board of directors. Thornberry was ... and Endocrinology for Merck & Co. Inc., where ... pipeline management in diabetes, osteoporosis, fertility and contraception. ... the program that resulted in the discovery of ...
Breaking Medicine Technology:Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 2Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 3Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine 2Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 2Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 3
... ... Release Formulation, CHICAGO, April ... sustained-release investigational compound to treat,Restless Legs Syndrome (RLS), showed that ... placebo, and was,generally well-tolerated when administered once-daily for 12 weeks., ...
... Expansion of Company,s Phase 3 Study for Wet AMD after ... 90-day Review ... announced,today that the U.S. Food and Drug Administration (FDA) has granted ... Phase 3 trial from 10 to 30 in the United States. ...
Cached Medicine Technology:Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 2Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 3Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 4Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 5Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 6FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S. 2FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S. 3
Aaron 2250 is a multipurpose electrosurgical generator with monoploar and bi-polar functions....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Designed to use all advantages of bipolar technique. C-2600 MP recommended to all specialties that uses the benefits of the bipolar techniques....
Medicine Products: